[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100493130":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":28,"locations":35,"responsibleParty":85,"collaborators":87,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":97,"sex":102,"minAge":103,"maxAge":10,"enrollmentInfo":104,"targetDuration":107,"studyType":108,"phases":10,"briefSummary":109,"conditions":110,"keywords":10,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"AIO-Studien-gGmbH","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"MIN Data Set",null,"Patients who did not receive a targeted therapy based on NGS results (outside of a clinical trial)",[13,14],"Other: Minimal documentation","Other: Extended documentation",{"label":16,"type":10,"description":17,"interventionNames":18},"EXT Data Set","Patients who received a targeted therapy based on NGS results (outside of a clinical trial)",[14],[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"Minimal documentation","Minimal data documentation only of patients without targeted therapy based on NGS results",[9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Extended documentation","Extended data documentation of patients with targeted therapy based on NGS results",[16,9],[29],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Marc Fischer","CONTACT","+49 30-8145344","44","marc.fischer@aio-studien-ggmbh.de",[36,53,69],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Praxis für interdisziplinäre Onkologie & Hämatologie","RECRUITING","Freiburg im Breisgau","Baden-Wurttemberg","79110","Germany","DE",{"type":45,"coordinates":46},"Point",[47,48],7.85222,47.9959,{"lat":48,"lon":47},[51],{"name":52,"role":31,"phone":10,"phoneExt":10,"email":10},"Matthias Zaiss, Dr. med.",{"facility":54,"status":55,"city":56,"state":40,"zip":57,"country":42,"countryCode":43,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Medizinische Fakultät Mannheim der Universität Heidelberg","NOT_YET_RECRUITING","Mannheim","68167",{"type":45,"coordinates":59},[60,61],8.46694,49.4891,{"lat":61,"lon":60},[64],{"name":65,"role":31,"phone":66,"phoneExt":67,"email":68},"Sonja Loges, Prof. Dr. Dr. med.","+49 621 383","1757","Sonja.Loges@medma.uni-heidelberg.de",{"facility":70,"status":55,"city":71,"state":72,"zip":73,"country":42,"countryCode":43,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Klinikum der Universität München","München","Bavaria","81377",{"type":45,"coordinates":75},[76,77],13.46314,48.69668,{"lat":77,"lon":76},[80],{"name":81,"role":31,"phone":82,"phoneExt":83,"email":84},"Benedikt Westphalen, Dr. med.","+49 89 4400","75250","christoph_benedikt.westphalen@med.uni-muenchen.de",{"type":86,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[88,91,93],{"name":89,"class":90},"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","INDUSTRY",{"name":92,"class":90},"Merck Sharp & Dohme LLC",{"name":94,"class":90},"Janssen-Cilag G.m.b.H","100493130","aio-bnho-comprehensive-clinico-genomics-database-network---aio-bnho-connect-100493130",false,"NCT05701150","AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT","CONNECT","Inclusion Criteria:\n\n* Diagnosis of advanced (i.e., locally advanced, inoperable, or metastatic) solid tumor, ineligible for curative surgery and\u002For curative systemic therapy\n* Available results of commercial or non-commercial RNA- and\u002For DNA-based multi-gene NGS panels with \\>30 genes analyzed; for non-commercial panels a list of all tested genes and multiple gene biomarkers (e.g., tumor mutational burden (TMB), microsatellite status) must be provided\n* Age ≥ 18 years\n* Signed and dated informed consent form (not applicable for inclusion of deceased patients)\n\nExclusion Criteria:\n\n* Diagnosis of NSCLC\u002FSCLC (C34) or mesothelioma (C45)\n* NGS results older than two years at the date of patient inclusion","ALL","18 Years",{"count":105,"type":106},3000,"ESTIMATED","36 Months","OBSERVATIONAL","National, retro- and prospective, observational, multicenter clinical research platform to connect clinical and genomic data of patients with advanced (locally advanced, inoperable, or metastatic) solid tumors (excluding NSCLC, SCLC, and mesothelioma) with results from multi-gene next-generation sequencing (NGS) panels (\\>30 genes)",[111],"Advanced Solid Tumor","2025-02-13",{"date":114,"type":115},"2025-02-17","ACTUAL",{"date":117,"type":115},"2022-12-08",{"date":119,"type":106},"2025-12",{"name":5,"class":6},3]